RE:Mental manipulation Growth in revenue and green eps: Q4 '23 and Q1 '24....ANVISA targeted approval timing and first big commercial contract for Brazil. That will take us on hard financial numbers to at least the historical high of just over $7. No fluff, hard core numbers and commercial contracts. All news to date from LABS for over a year now has been positive including the big improvements in their balance sheet and cash position. No fluff, hard core numbers speak louder than b.s.
At the end of the day, it really doesn't matter what anyone thinks or says because what we are waiting for has been set in motion years ago, including the day Medipharm Labs began to exist as a company and being the first company as well focused on extraction for pharmaceutical applications...commercializing the life time work of Dr. Mechoulam et al.
Clinical trials, scientific evidence that has no fluff, no b.s., hard core facts.
Also, you were complaining a little bit that you only saw 6 clinical trials that LABS published in a press release. Easy math says that at least 14 of those clinical trials that have not been disclosed are with their pharma partner and secretive for competitive reasons.
Buy the sh*t out of it.